Elizabeth Mellins
Pediatric Rheumatology · Palo Alto, CANPI 1093859530
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,424 of the $4,424 with a category attached, or 100.0%. Boehringer Ingelheim accounts for 65.1% of it on its own, with 1 other manufacturer making up the rest.
Across 2 payments — averaging $2212.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- GSK$2K
Across 15 payments — averaging $143,726 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2M
- Novartis$156K
What the payments were for
- Consulting fees$4,424100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $2,880 |
| GSK | 1 | $1,544 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$2,880
How this compares
$4,424 in reported general payments places this provider in the 80th percentile of 39 pediatric rheumatology providers in California.
Other pediatric rheumatology in Palo Alto
- Vivian SaperPalo Alto$47K
- Jennifer FrankovichPalo Alto$45K
- Rebecca KunderPalo Alto$1K
- Jully PadamPalo Alto$272
- Joyce HsuPalo Alto$263
- Cristina SaezPalo Alto$177
- Imelda BalboniPalo Alto$142
- Sivakanthan KasinathanPalo Alto$142
- Rajdeep PooniPalo Alto$122
- William SoulsbySan Francisco$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.